Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin

Bethany L. Johnson-Kerner, Faizzan S. Ahmad, Alejandro Garcia Diaz, John Palmer Greene, Steven J. Gray, Richard Jude Samulski, Wendy K. Chung, Rudy Van Coster, Paul Maertens, Scott A. Noggle, Christopher E. Henderson, Hynek Wichterle

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Giant axonal neuropathy (GAN) is a progressive neurodegenerative disease caused by autosomal recessive mutations in the GAN gene resulting in a loss of a ubiquitously expressed protein, gigaxonin. Gene replacement therapy is a promising strategy for treatment of the disease; however, the effectiveness and safety of gigaxonin reintroduction have not been tested in human GAN nerve cells. Herewe report the derivation of induced pluripotent stem cells (iPSCs) from three GAN patients with different GAN mutations. Motor neurons differentiated from GAN iPSCs exhibit accumulation of neurofilament (NF-L) and peripherin (PRPH) protein and formation of PRPH aggregates, the key pathological phenotypes observed in patients. Introduction of gigaxonin either using a lentiviral vector or as a stable transgene resulted in normalization of NEFL and PRPH levels in GAN neurons and disappearance of PRPH aggregates. Importantly, overexpression of gigaxonin had no adverse effect on survival of GAN neurons, supporting the feasibility of gene replacement therapy. Our findings demonstrate that GAN iPSCs provide a novel model for studying human GAN neuropathologies and for the development and testing of new therapies in relevant cell types.

Original languageEnglish (US)
Pages (from-to)1420-1431
Number of pages12
JournalHuman Molecular Genetics
Volume24
Issue number5
DOIs
StatePublished - Jan 1 2015

Fingerprint

Giant Axonal Neuropathy
Intermediate Filament Proteins
Induced Pluripotent Stem Cells
Motor Neurons
Peripherins
Neurons
Genetic Therapy
Neurofilament Proteins
Mutation
Transgenes
Neurodegenerative Diseases

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin. / Johnson-Kerner, Bethany L.; Ahmad, Faizzan S.; Diaz, Alejandro Garcia; Greene, John Palmer; Gray, Steven J.; Samulski, Richard Jude; Chung, Wendy K.; Van Coster, Rudy; Maertens, Paul; Noggle, Scott A.; Henderson, Christopher E.; Wichterle, Hynek.

In: Human Molecular Genetics, Vol. 24, No. 5, 01.01.2015, p. 1420-1431.

Research output: Contribution to journalArticle

Johnson-Kerner, BL, Ahmad, FS, Diaz, AG, Greene, JP, Gray, SJ, Samulski, RJ, Chung, WK, Van Coster, R, Maertens, P, Noggle, SA, Henderson, CE & Wichterle, H 2015, 'Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin', Human Molecular Genetics, vol. 24, no. 5, pp. 1420-1431. https://doi.org/10.1093/hmg/ddu556
Johnson-Kerner, Bethany L. ; Ahmad, Faizzan S. ; Diaz, Alejandro Garcia ; Greene, John Palmer ; Gray, Steven J. ; Samulski, Richard Jude ; Chung, Wendy K. ; Van Coster, Rudy ; Maertens, Paul ; Noggle, Scott A. ; Henderson, Christopher E. ; Wichterle, Hynek. / Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin. In: Human Molecular Genetics. 2015 ; Vol. 24, No. 5. pp. 1420-1431.
@article{9c7221915a4042bda50f6bb2b6b94e7e,
title = "Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin",
abstract = "Giant axonal neuropathy (GAN) is a progressive neurodegenerative disease caused by autosomal recessive mutations in the GAN gene resulting in a loss of a ubiquitously expressed protein, gigaxonin. Gene replacement therapy is a promising strategy for treatment of the disease; however, the effectiveness and safety of gigaxonin reintroduction have not been tested in human GAN nerve cells. Herewe report the derivation of induced pluripotent stem cells (iPSCs) from three GAN patients with different GAN mutations. Motor neurons differentiated from GAN iPSCs exhibit accumulation of neurofilament (NF-L) and peripherin (PRPH) protein and formation of PRPH aggregates, the key pathological phenotypes observed in patients. Introduction of gigaxonin either using a lentiviral vector or as a stable transgene resulted in normalization of NEFL and PRPH levels in GAN neurons and disappearance of PRPH aggregates. Importantly, overexpression of gigaxonin had no adverse effect on survival of GAN neurons, supporting the feasibility of gene replacement therapy. Our findings demonstrate that GAN iPSCs provide a novel model for studying human GAN neuropathologies and for the development and testing of new therapies in relevant cell types.",
author = "Johnson-Kerner, {Bethany L.} and Ahmad, {Faizzan S.} and Diaz, {Alejandro Garcia} and Greene, {John Palmer} and Gray, {Steven J.} and Samulski, {Richard Jude} and Chung, {Wendy K.} and {Van Coster}, Rudy and Paul Maertens and Noggle, {Scott A.} and Henderson, {Christopher E.} and Hynek Wichterle",
year = "2015",
month = "1",
day = "1",
doi = "10.1093/hmg/ddu556",
language = "English (US)",
volume = "24",
pages = "1420--1431",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin

AU - Johnson-Kerner, Bethany L.

AU - Ahmad, Faizzan S.

AU - Diaz, Alejandro Garcia

AU - Greene, John Palmer

AU - Gray, Steven J.

AU - Samulski, Richard Jude

AU - Chung, Wendy K.

AU - Van Coster, Rudy

AU - Maertens, Paul

AU - Noggle, Scott A.

AU - Henderson, Christopher E.

AU - Wichterle, Hynek

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Giant axonal neuropathy (GAN) is a progressive neurodegenerative disease caused by autosomal recessive mutations in the GAN gene resulting in a loss of a ubiquitously expressed protein, gigaxonin. Gene replacement therapy is a promising strategy for treatment of the disease; however, the effectiveness and safety of gigaxonin reintroduction have not been tested in human GAN nerve cells. Herewe report the derivation of induced pluripotent stem cells (iPSCs) from three GAN patients with different GAN mutations. Motor neurons differentiated from GAN iPSCs exhibit accumulation of neurofilament (NF-L) and peripherin (PRPH) protein and formation of PRPH aggregates, the key pathological phenotypes observed in patients. Introduction of gigaxonin either using a lentiviral vector or as a stable transgene resulted in normalization of NEFL and PRPH levels in GAN neurons and disappearance of PRPH aggregates. Importantly, overexpression of gigaxonin had no adverse effect on survival of GAN neurons, supporting the feasibility of gene replacement therapy. Our findings demonstrate that GAN iPSCs provide a novel model for studying human GAN neuropathologies and for the development and testing of new therapies in relevant cell types.

AB - Giant axonal neuropathy (GAN) is a progressive neurodegenerative disease caused by autosomal recessive mutations in the GAN gene resulting in a loss of a ubiquitously expressed protein, gigaxonin. Gene replacement therapy is a promising strategy for treatment of the disease; however, the effectiveness and safety of gigaxonin reintroduction have not been tested in human GAN nerve cells. Herewe report the derivation of induced pluripotent stem cells (iPSCs) from three GAN patients with different GAN mutations. Motor neurons differentiated from GAN iPSCs exhibit accumulation of neurofilament (NF-L) and peripherin (PRPH) protein and formation of PRPH aggregates, the key pathological phenotypes observed in patients. Introduction of gigaxonin either using a lentiviral vector or as a stable transgene resulted in normalization of NEFL and PRPH levels in GAN neurons and disappearance of PRPH aggregates. Importantly, overexpression of gigaxonin had no adverse effect on survival of GAN neurons, supporting the feasibility of gene replacement therapy. Our findings demonstrate that GAN iPSCs provide a novel model for studying human GAN neuropathologies and for the development and testing of new therapies in relevant cell types.

UR - http://www.scopus.com/inward/record.url?scp=84924440715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924440715&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddu556

DO - 10.1093/hmg/ddu556

M3 - Article

C2 - 25398950

AN - SCOPUS:84924440715

VL - 24

SP - 1420

EP - 1431

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 5

ER -